Cargando…
One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
PURPOSE: To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO). METHODS: Interventional case series documenting 12-month outcomes of intravitreal ziv-aflibercept (1.25 mg in 0.05 mL) in 6 patients with...
Autores principales: | Eldeeb, Mohab, Chan, Errol W., Dedhia, Chintan J., Mansour, Ahmad, Chhablani, Jay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731707/ https://www.ncbi.nlm.nih.gov/pubmed/29260119 http://dx.doi.org/10.1016/j.ajoc.2017.10.011 |
Ejemplares similares
-
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016) -
Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015) -
Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019) -
Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Sen, Alok, et al.
Publicado: (2015) -
Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)